Appointment of Chief Executive Officer
Filed with ASX · · 2 pages · English
Earlier from Dimerix
- Update presentation - interim data
- Positive interim analysis of DMX-200 phase II data
- Appendix 4E
- Response to ASX Price and Volume Query
- Outcomes of DMX-200 pre-IND meeting with the FDA
Later from Dimerix
- Recruitment of Part A of Phase 2 Trial of DMX-200 Completed
- Dimerix Raises $2 million to Advance Clinical Program
- Key Patent Allowed in Japan
- Corporate Presentation
- Receipt of $420k Research & Development Tax Refund
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix